AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 02, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 4, 2017 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2017 financial results and a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 17334187.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858.717.2310 Email: [email protected]
